Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BREVICON 21-DAY vs ALYACEN 1/35
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive containing ethinyl estradiol and norethindrone. Suppresses gonadotropin (FSH, LH) release via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation. Increases viscosity of cervical mucus and alters endometrial lining to impede sperm penetration and implantation.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.
Prevention of pregnancy
Prevention of pregnancy
One tablet (0.5 mg norethindrone and 0.035 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days off.
One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
Norethindrone: 7-8 hours; Ethinyl estradiol: 13-17 hours. Clinical context: Steady state reached within 5-7 days; missed pills may reduce contraceptive efficacy.
Norethindrone: 8-11 hours (terminal); ethinyl estradiol: 10-20 hours (terminal). The half-life supports once-daily dosing for oral contraceptive efficacy.
Ethinyl estradiol: primarily metabolized via CYP3A4; undergoes first-pass metabolism in gut wall and liver. Norethindrone: metabolized via reduction and conjugation, primarily excreted as glucuronide conjugates.
Ethinyl estradiol: primarily hepatic via CYP3A4; norethindrone: hepatic reduction and sulfate conjugation.
Urine (50-60% as metabolites, <10% unchanged); feces (30-40% as metabolites); biliary (minor).
Renal excretion of metabolites (primarily ethinyl estradiol and norethindrone conjugates) accounts for approximately 50-60% of elimination; fecal excretion accounts for 30-40%. Unchanged drug excretion is minimal (<5%).
Norethindrone: 61% bound to albumin and SHBG; Ethinyl estradiol: 97-98% bound to albumin, SHBG not involved.
Norethindrone: 61% bound to albumin and SHBG; ethinyl estradiol: 97-98% bound to albumin.
Norethindrone: 4-5 L/kg; Ethinyl estradiol: 3-4 L/kg. High Vd indicates extensive tissue distribution, including breast and reproductive tissues.
Norethindrone: 3.8-4.5 L/kg; ethinyl estradiol: 2.0-4.0 L/kg. Large Vd indicates extensive tissue distribution.
Oral: Norethindrone ~64% (first-pass metabolism); Ethinyl estradiol ~45% (first-pass metabolism, high interindividual variability).
Oral: Norethindrone ~64%, ethinyl estradiol ~38-48% (due to first-pass metabolism).
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment; use with caution.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention and electrolyte disturbances.
Contraindicated in Child-Pugh class B or C (moderate to severe hepatic impairment). No adjustment needed for Child-Pugh class A.
Contraindicated in patients with hepatic impairment, including Child-Pugh class B or C, due to impaired metabolism of estrogen and progestin. Not recommended in patients with active liver disease or history of liver tumors.
Use not indicated in pediatric patients before menarche. After menarche, dose is same as adult.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults. Safety and efficacy established for contraception; weight-based dosing not applicable.
Not approved for use in postmenopausal women. No elderly-specific dose adjustments; use not indicated in this population.
Not indicated for use after menopause due to lack of benefit and increased risks (e.g., cardiovascular, thromboembolic events). If used, monitor for fluid retention, hypertension, and glucose intolerance.
Cigarette smoking increases risk of serious cardiovascular events (thrombosis, myocardial infarction, stroke) from oral contraceptive use, especially in women >35 years old and those smoking ≥15 cigarettes/day.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Increased risk of venous thromboembolism (VTE) and arterial thrombosis, especially in smokers or those with predisposing factors,Elevated risk of cardiovascular events in women with hypertension, diabetes, or hyperlipidemias,Hepatic neoplasia risk with long-term use,Increased risk of gallbladder disease,May cause fluid retention and exacerbate conditions like migraine, seizure disorders, renal impairment
Thrombotic disorders (e.g., DVT, PE, stroke, MI),Cerebrovascular disease,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate and lipid effects,Ocular lesions,Hereditary angioedema,Chloasma,Menstrual irregularities,Pregnancy exclusion prior to initiation
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease,Known or suspected breast carcinoma,Estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Pregnancy or suspected pregnancy,Known or suspected pregnancy,Active liver disease, benign or malignant hepatic tumors (current or history),Hypersensitivity to any component
Venous or arterial thrombotic/thromboembolic disease (current or history),Cerebrovascular disease,Coronary artery disease,Known or suspected breast cancer,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35
No significant food interactions. Grapefruit juice may slightly increase ethinylestradiol levels, but not clinically relevant. Avoid excessive alcohol.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinically not a concern. Avoid excessive alcohol, which may impair liver function and increase estrogen exposure. Maintain a healthy diet, as weight gain is possible.
Pregnancy category X. Contraindicated in pregnancy due to established risk of fetal harm. First trimester: Exposure associated with cardiovascular defects (e.g., VSD), limb reduction defects, and neural tube defects; risk increases with dose and duration. Second and third trimesters: Potential for fetal adrenal suppression, masculinization of female genitalia (from progestin component), and long-term neurodevelopmental effects. Postmarketing data confirm elevated risk of congenital anomalies.
Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including cardiovascular defects and limb reduction defects. Second/third trimesters: Potential for urogenital abnormalities and feminization of male fetus. Exposure is associated with subsequent development of clear cell adenocarcinoma of vagina/cervix in female offspring (DES-related).
Excreted in human breast milk; M/P ratio not established. Norethindrone (0.1% of maternal dose) and ethinyl estradiol (0.02% of maternal dose) detected in milk. Possible adverse effects on lactation (decreased milk production) and infant (jaundice, breast enlargement). Use only if clearly needed; smallest effective dose recommended. American Academy of Pediatrics considers use compatible with breastfeeding when standard doses are used, but caution advised.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. M/P ratio: Not specifically determined for this combination; ethinyl estradiol M/P ratio ~0.02-0.04. Use may reduce milk production and quality. Breastfeeding not recommended during use. Alternative contraception advised.
Contraindicated in pregnancy; no dose adjustment applicable as drug must be discontinued. If inadvertent exposure occurs, stop immediately and counsel regarding risks. No pharmacokinetic studies in pregnancy due to contraindication; dose adjustment not relevant.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue medication immediately upon pregnancy detection.
Brevinor-21 is a combined oral contraceptive containing norethisterone and ethinylestradiol. It suppresses ovulation and alters cervical mucus. Monitor for thromboembolic events; contraindicated in smokers over 35. Breakthrough bleeding may occur, especially in first cycles. Missed pill management: if one pill missed, take it ASAP; if two or more missed, use backup contraception.
ALYACEN 1/35 is a combination oral contraceptive containing ethinyl estradiol 35 mcg and norgestimate 1 mg. It is indicated for the prevention of pregnancy and for the treatment of moderate acne vulgaris in females ≥15 years of age who desire an oral contraceptive. Monitor for thromboembolic events, especially in smokers over 35 or those with migraine with aura. Use with caution in patients with liver impairment or history of cholestatic jaundice. The pill-free interval should not exceed 7 days; missed pills increase ovulation risk. Consider non-hormonal backup if vomiting or diarrhea occurs within 4 hours of dosing.
Take one pill daily at the same time for 21 days, then 7 pill-free days.,Use backup contraception (e.g., condoms) if you miss pills or start late.,Common side effects: nausea, breast tenderness, mood changes; usually improve.,Seek medical help for severe leg pain, chest pain, or sudden severe headache.,Smoking increases risk of serious cardiovascular side effects.
Take one tablet daily at the same time each day; do not skip doses.,Use an additional non-hormonal contraceptive (e.g., condoms) if you miss a pill, have vomiting, or diarrhea.,Smoking while on this pill increases the risk of blood clots and stroke, especially if you are over 35.,Contact your healthcare provider immediately if you have chest pain, leg pain/swelling, sudden vision changes, or severe headache.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BREVICON 21-DAY vs ALYACEN 1/35, answered by our medical review team.
BREVICON 21-DAY is a Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and norethindrone. Suppresses gonadotropin (FSH, LH) release via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation. Increases viscosity of cervical mucus and alters endometrial lining to impede sperm penetration and implantation.. ALYACEN 1/35 is a Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BREVICON 21-DAY and ALYACEN 1/35 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BREVICON 21-DAY is: One tablet (0.5 mg norethindrone and 0.035 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days off.. The standard adult dose of ALYACEN 1/35 is: One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BREVICON 21-DAY and ALYACEN 1/35 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BREVICON 21-DAY is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to established risk of fetal harm. First trimester: Exposure associated with cardiovascular defects (e.g., VSD), limb reducti. ALYACEN 1/35 is classified as Category C. Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.